Last 12 months
Inside the activity.
0 purchase rows · 142 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 32 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 31 |
| Mar 2026 | 0 | 21 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 23 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 8 |
| Sep 2026 | 0 | 26 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2019 Filed Jun 17, 2019 21:24 UTC |
Riley Antony AChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $31.42 | $0.00 |
DisclosureSEC source: 0001209191-19-037449 · doc4.xml · derivative · entry 1 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The options were awarded on June 1, 2019 and vest ratably over a four-year period. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 01:07 UTC |
Riley Antony AChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $25.02 | $0.00 |
DisclosureSEC source: 0001209191-19-021266 · doc4.xml · derivative · entry 1 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-03-22 F1 · derivative.exercise_date: The options were awarded on March 22, 2019 and vest ratably over a four-year period. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 22:53 UTC |
Gangolli Julian SDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $22.75 | $0.00 |
DisclosureSEC source: 0001209191-19-017476 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-01 F1 · derivative.exercise_date: The options were awarded on March 1, 2019 and vest monthly over a three-year period. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 21:28 UTC |
Krishnan SumaDirector · Chief Operating Officer · 10% owner
|
PurchaseCommon Stock | 25,000 | $20.00 | $500,000.00 |
DisclosureSEC source: 0001209191-18-055882 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,001,462 Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 21:27 UTC |
Krishnan Krish SDirector · President and CEO · 10% owner
|
PurchaseCommon Stock | 25,000 | $20.00 | $500,000.00 |
DisclosureSEC source: 0001209191-18-055881 · doc4.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036,462 Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:08 UTC |
Krishnan SumaDirector · Chief Operating Officer · 10% owner
|
PurchaseCommon Stock | 1,018 | $12.45 | $12,674.10 |
DisclosureSEC source: 0001209191-18-036328 · doc4.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,976,462 F3 · price: This transaction was executed in multiple trades ranging from $12.11 to $12.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:08 UTC |
Krishnan SumaDirector · Chief Operating Officer · 10% owner
|
PurchaseCommon Stock | 13,116 | $11.15 | $146,177.82 |
DisclosureSEC source: 0001209191-18-036328 · doc4.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,975,444 F2 · price: This transaction was executed in multiple trades ranging from $11.10 to $12.00. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:08 UTC |
Krishnan SumaDirector · Chief Operating Officer · 10% owner
|
PurchaseCommon Stock | 10,866 | $10.75 | $116,757.34 |
DisclosureSEC source: 0001209191-18-036328 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,962,328 F1 · price: This transaction was executed in multiple trades ranging from $10.73 to $11.00. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:01 UTC |
Krishnan SumaDirector · Chief Operating Officer · 10% owner
|
OtherCommon Stock | 16,213 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-035583 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,951,462 F1 · shares: Award of restricted stock. F1 · price: Award of restricted stock. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:00 UTC |
Krishnan Krish SDirector · President and CEO · 10% owner
|
OtherCommon Stock | 26,213 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-035581 · doc4.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011,462 F1 · shares: Award of restricted stock. F1 · price: Award of restricted stock. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 23:43 UTC |
JANNEY DANIELDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0001209191-18-035373 · doc4.xml · derivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-31 F1 · derivative.exercise_date: The options were awarded on May 31, 2018 and vest monthly over a one-year period. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:53 UTC |
ROSSI DINO ADirector
|
GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0001209191-18-035197 · doc4.xml · derivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-31 F1 · derivative.exercise_date: The options were awarded on May 31, 2018 and vest monthly over a one-year period. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:49 UTC |
NORBY R DOUGLASDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0001209191-18-035175 · doc4.xml · derivative · entry 1 NORBY R DOUGLAS · CIK 0001227001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-31 F1 · derivative.exercise_date: The options were awarded on May 31, 2018 and vest monthly over a one-year period. Read SEC document |
| May 22, 2018 Filed May 24, 2018 21:28 UTC |
Riley Antony AChief Financial Officer
|
PurchaseCommon Stock | 2,800 | $10.75 | $30,100.00 |
DisclosureSEC source: 0001209191-18-033088 · doc4.xml · nonDerivative · entry 1 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:27 UTC |
NORBY R DOUGLASDirector
|
PurchaseCommon Stock | 9,000 | $10.42 | $93,780.00 |
DisclosureSEC source: 0001209191-18-029567 · doc4.xml · nonDerivative · entry 1 NORBY R DOUGLAS · CIK 0001227001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.31 to $10.60. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 20:43 UTC |
Krishnan Krish SDirector · President and CEO · 10% owner
|
PurchaseCommon Stock | 50,000 | $11.00 | $550,000.00 |
DisclosureSEC source: 0000925421-18-000155 · edgar.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,985,249 Read SEC document |
| March 08, 2018 Filed May 24, 2018 21:28 UTC |
Riley Antony AChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0001209191-18-033088 · doc4.xml · derivative · entry 2 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-03-08 F1 · derivative.exercise_date: The options were awarded on March 8, 2018 and vest ratably over a four-year period. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:30 UTC |
ROSSI DINO ADirector
|
ConversionSeries A Convertible Preferred Stock · Derivative | 123,691 | $0.00 | $0.00 |
DisclosureSEC source: 0000925421-17-000365 · edgar.xml · derivative · entry 2 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 123,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A convertible preferred stock converted on a one-to-one basis into 123,691 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.exercise_date: The Series A convertible preferred stock converted on a one-to-one basis into 123,691 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.expiration_date: The Series A convertible preferred stock converted on a one-to-one basis into 123,691 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:30 UTC |
ROSSI DINO ADirector
|
ConversionCommon Stock | 123,691 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000925421-17-000365 · edgar.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A convertible preferred stock converted on a one-to-one basis into 123,691 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:28 UTC |
JANNEY DANIELDirector
|
ConversionSeries A Convertible Preferred Stock · Derivative | 124,456 | $0.00 | $0.00 |
DisclosureSEC source: 0000925421-17-000363 · edgar.xml · derivative · entry 3 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 124,456 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A convertible preferred stock converted on a one-to-one basis into 124,456 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.exercise_date: The Series A convertible preferred stock converted on a one-to-one basis into 124,456 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.expiration_date: The Series A convertible preferred stock converted on a one-to-one basis into 124,456 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F2 · ownership.nature: Directly beneficially owned by Alta Bioequities, L.P. F3 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The reporting person is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:28 UTC |
JANNEY DANIELDirector
|
ConversionCommon Stock | 124,456 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000925421-17-000363 · edgar.xml · nonDerivative · entry 2 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 455,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A convertible preferred stock converted on a one-to-one basis into 124,456 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F2 · ownership.nature: Directly beneficially owned by Alta Bioequities, L.P. F3 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The reporting person is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:28 UTC |
JANNEY DANIELDirector
|
PurchaseCommon Stock | 200,000 | $10.00 | $2,000,000.00 |
DisclosureSEC source: 0000925421-17-000363 · edgar.xml · nonDerivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 330,590 F2 · ownership.nature: Directly beneficially owned by Alta Bioequities, L.P. F3 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The reporting person is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:25 UTC |
Krishnan SumaDirector · Chief Operating Officer · 10% owner
|
ConversionSeries A Convertible Preferred Stock · Derivative | 112,162 | $0.00 | $0.00 |
DisclosureSEC source: 0000925421-17-000361 · edgar.xml · derivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 0 Underlying: Common Stock · 112,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.exercise_date: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.expiration_date: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F2 · ownership.nature: Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:25 UTC |
Krishnan SumaDirector · Chief Operating Officer · 10% owner
|
ConversionCommon Stock | 112,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000925421-17-000361 · edgar.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 112,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F2 · ownership.nature: Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:25 UTC |
Krishnan SumaDirector · Chief Operating Officer · 10% owner
|
PurchaseCommon Stock | 100,000 | $10.00 | $1,000,000.00 |
DisclosureSEC source: 0000925421-17-000361 · edgar.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,935,249 Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:22 UTC |
Krishnan Krish SDirector · President and CEO · 10% owner
|
ConversionSeries A Convertible Preferred Stock · Derivative | 112,162 | $0.00 | $0.00 |
DisclosureSEC source: 0000925421-17-000358 · edgar.xml · derivative · entry 4 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 0 Underlying: Common Stock · 112,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.exercise_date: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.expiration_date: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F2 · ownership.nature: Directly beneficially owned by the Krishnan Family Trust. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:22 UTC |
Krishnan Krish SDirector · President and CEO · 10% owner
|
ConversionCommon Stock | 112,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000925421-17-000358 · edgar.xml · nonDerivative · entry 2 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 112,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F2 · ownership.nature: Directly beneficially owned by the Krishnan Family Trust. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:22 UTC |
Krishnan Krish SDirector · President and CEO · 10% owner
|
PurchaseCommon Stock | 100,000 | $10.00 | $1,000,000.00 |
DisclosureSEC source: 0000925421-17-000358 · edgar.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,935,249 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.